Casimersen Patent Expiration

Casimersen is used for treating Duchenne Muscular Dystrophy (DMD) in patients with a mutation of the DMD gene amenable to exon 45 skipping. It was first introduced by Sarepta Therapeutics Inc in its drug Amondys 45 on Feb 25, 2021.


Casimersen Patents

Given below is the list of patents protecting Casimersen, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Amondys 45 US10287586 Antisense molecules and methods for treating pathologies Nov 12, 2030 Sarepta Theraps Inc
Amondys 45 US10781450 Antisense molecules and methods for treating pathologies Nov 12, 2030 Sarepta Theraps Inc
Amondys 45 US9228187 Antisense molecules and methods for treating pathologies Nov 12, 2030 Sarepta Theraps Inc
Amondys 45 US9758783 Antisense molecules and methods for treating pathologies Nov 12, 2030 Sarepta Theraps Inc
Amondys 45 US8524880 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Apr 02, 2026 Sarepta Theraps Inc
Amondys 45 US9447415 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Amondys 45 USRE48960 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun 28, 2025 Sarepta Theraps Inc
Amondys 45 US10533174 Splice-region antisense composition and method May 04, 2021

(Expired)

Sarepta Theraps Inc
Amondys 45 US9416361 Splice-region antisense composition and method May 04, 2021

(Expired)

Sarepta Theraps Inc



Casimersen's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List